• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:柯文炳,陈焱生.胸腺肽治疗肝硬化并发自发性腹膜炎的疗效观察[J].药学研究,2017,36(1):56-58[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 3592次   下载 2990次 本文二维码信息
码上扫一扫!
胸腺肽治疗肝硬化并发自发性腹膜炎的疗效观察
柯文炳,陈焱生
字体:加大+|默认|缩小-
(鄂东医疗集团市中医医院<市传染病医院>,湖北 黄石 435003)
摘要:
目的 观察临床上应用胸腺肽对肝硬化并发自发性腹膜炎的治疗效果。方法 入选我院住院治疗的98例肝硬化并发自发性腹膜炎患者,随机分为治疗组(n=55)和对照组(n=43),两组均给予两周疗程的抗感染(三代头孢)、护肝、利尿、白蛋白和血浆支持等综合治疗,在此基础上,治疗组加用αl胸腺肽1.6 mg,皮下注射,隔日一次。观察并记录两组患者治疗前后腹水PMN计数和腹围大小,以及治疗期间患者不良反应发生情况。结果 治疗组在痊愈率(32.7%vs23.3%,χ2=3.914,P=0.043)、总有效率(85.4%vs72.1%,χ2=34.065,P=0.038)方面均优于对照组,组间比较具有统计学意义(P<0.05);此外,治疗组在腹水PMN计数下降和腹围缩小等方面均显著高于对照组(P<0.05或P<0.01)。结论 胸腺肽在治疗肝硬化并发自发性腹膜炎方面临床疗效良好,尤其在症状改善和腹水消退等控制病情方面具有一定的临床价值。
关键词:  胸腺肽  肝硬化  自发性细菌性腹膜炎
DOI:10.13506/j.cnki.jpr.2017.01.016
基金项目:
To observe the curative effect of thymosin in treatment of liver cirrhosis complicated with spontaneous bacterial peritonitis.
KE Wenbing,CHEN Yansheng
(Edong Healthcare Huangshi TCM Hospital,Huangshi 435003,China)
Abstract:
Objective To observe the clinical application effect of thymosin treatment of liver cirrhosis complicated with spontaneous bacterial peritonitis.Methods 98 cases of cirrhosis complicated with spontaneous bacterial peritonitis in our hospital were enrolled,and randomly divided into treatment group (n=55) and control group (n=43).Anti-infection of the two groups were given two weeks of treatment (three generation cephalosporins),protecting liver,diuresis,plasma albumin and supportive treatment.On this basis,the treatment group was treated with thymosin alpha l 1.6 mg,subcutaneous injection,once every two days.Observe and record the two groups of patients before and after treatment of ascites PMN count and abdominal circumference size,and the occurrence of adverse reactions during treatment of patients.Results The treatment group in the cure rate (32.7%vs23.3%,χ2=3.914,P=0.043),the total effective rate (85.4%vs72.1%,χ2=34.065,P=0.038) were better than the control group,comparison between groups was statistically significant (P<0.05);In addition,the treatment group in the ascites decreased PMN count and waist circumference were significantly higher than that the control group of narrow etc. (P<0.05 or P<0.01).Conclusion Thymosin good clinical efficacy in the treatment of liver cirrhosis complicated with spontaneous peritonitis, especially had certain clinical value in improving symptoms and disease control ascites.
Key words:  Thymosin  Cirrhosis  Spontaneous bacterial peritonitis
今日访问量:2328    总访问量:55338696
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司